RARA and acute promyelocytic leukemia: Additionally, APL-like variants with atypical genetic rearrangements (e.g., PLZF-RARA) frequently resist ATRA/ATO, necessitating alternative approaches such as chemotherapy or histone deacetylase inhibitors (12).